Article Information
History
- September 16, 2022.
Article Versions
- Version 1 (May 23, 2022 - 09:45).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Alvin X. Han1,*,
- Amy Toporowski2,
- Jilian A. Sacks3,
- Mark D. Perkins3,
- Sylvie Briand3,
- Maria van Kerkhove3,
- Emma Hannay2,
- Sergio Carmona2,
- Bill Rodriguez2,
- Edyth Parker4,
- Brooke E. Nichols1,2,5,† and
- Colin A. Russell1,5,†,*
- 1Department of Medical Microbiology & Infection Prevention, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands
- 2Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland
- 3Department of Epidemic and Pandemic Preparedness and Prevention, Emergency Preparedness Programme, World Health Organization, Geneva, Switzerland
- 4Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA
- 5Department of Global Health, School of Public Health, Boston University, Boston, MA, USA
- ↵*Corresponding authors. Email: x.han{at}amsterdamumc.nl and c.a.russell{at}amsterdamumc.nl
↵† Contributed equally
Posted September 16, 2022.
SARS-CoV-2 diagnostic testing rates determine the sensitivity of genomic surveillance programs
